第一作者机构:[1]Shanghai Jiao Tong Univ, Chest Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Chu T.,Han B.,Yu Z.,et al.First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis[J].JOURNAL OF THORACIC ONCOLOGY.2023,18(11):S616-S616.
APA:
Chu, T.,Han, B.,Yu, Z.,Wang, J.,Zhao, Y....&Geng, N..(2023).First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis.JOURNAL OF THORACIC ONCOLOGY,18,(11)
MLA:
Chu, T.,et al."First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis".JOURNAL OF THORACIC ONCOLOGY 18..11(2023):S616-S616